| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (NCT05461430) | Travera Inc | 2022-07-15 |
| A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) (NCT05239728) | Merck Sharp & Dohme LLC | 2022-03-15 |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies (NCT04895748) | Novartis Pharmaceuticals | 2021-11-30 |
| A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma (NCT05104905) | Faron Pharmaceuticals Ltd | 2021-10-07 |
| An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION) (NCT04941768) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2021-08-09 |
| Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma (NCT04387500) | West China Hospital | 2021-07-01 |
| A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) (NCT04846920) | Merck Sharp & Dohme LLC | 2021-06-14 |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (NCT04895709) | Bristol-Myers Squibb | 2021-05-27 |
| A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) (NCT04736706) | Merck Sharp & Dohme LLC | 2021-04-14 |
| A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) (NCT04586231) | Merck Sharp & Dohme LLC | 2021-02-25 |
| Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) (NCT04626518) | Merck Sharp & Dohme LLC | 2020-12-17 |
| Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) (NCT04626479) | Merck Sharp & Dohme LLC | 2020-12-16 |
| Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors (NCT04602702) | Sunnybrook Health Sciences Centre | 2020-12-01 |
| Mobile Intervention - Physical Activity in Cancer Treatment (NCT03671304) | University of Texas Southwestern Medical Center | 2020-11-20 |
| A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) (NCT04489771) | Merck Sharp & Dohme LLC | 2020-09-13 |
| Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC (NCT04496089) | Telix Pharmaceuticals (Innovations) Pty Limited | 2020-08-01 |
| A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (NCT04338269) | Hoffmann-La Roche | 2020-07-28 |
| A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies (NCT04544748) | AO GENERIUM | 2020-07-22 |
| A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) (NCT04195750) | Merck Sharp & Dohme LLC | 2020-02-27 |
| Identification of Novel Biomarkers of Response to Systemic Treatments in Renal Cell Cancer (NCT04060537) | CCTU- Cancer Theme | 2020-01-01 |
| REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (NCT03916458) | Pfizer | 2019-12-17 |
| Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations (NCT04113486) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2019-10-01 |
| A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (NCT04028245) | Columbia University | 2019-08-15 |
| Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to Nephron-sparing Surgery for Renal Tumor. (NCT03943771) | University Hospital, Bordeaux | 2019-07-01 |
| Three-dimensional Virtual Imaging to Improve the Accuracy of Standard CT-based Nephrometric Scores: a Prospective Multicentric Observational Study (NCT05729763) | San Luigi Gonzaga Hospital | 2019-06-01 |
| Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer (NCT03111901) | William Grosh, MD | 2018-10-29 |
| PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors (NCT03685591) | Pfizer | 2018-10-04 |
| a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy (NCT03900364) | Salzburger Landeskliniken | 2018-09-03 |
| Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma (NCT02782715) | University of Wisconsin, Madison | 2018-06-28 |
| "Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC" (NCT03538717) | Pfizer | 2018-04-19 |
| KIDSTAGE- Staging of Kidney Cancer Using Dual Time PET/CT and Other Biomarkers (NCT04295174) | Odense University Hospital | 2018-01-01 |
| Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing (NCT03109015) | Duke University | 2017-09-27 |
| A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer (NCT03165721) | National Cancer Institute (NCI) | 2017-08-16 |
| Savolitinib vs. Sunitinib in MET-driven PRCC. (NCT03091192) | AstraZeneca | 2017-07-25 |
| A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (NCT03138512) | Bristol-Myers Squibb | 2017-07-07 |
| Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types (NCT03012581) | UNICANCER | 2017-06-16 |
| Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers) (NCT02978118) | Duke University | 2017-03-07 |
| Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (NCT02917772) | AIO-Studien-gGmbH | 2016-10-01 |
| Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma (NCT02729194) | University of Michigan Rogel Cancer Center | 2016-06-01 |
| Glycosaminoglycan Scores as Monitoring Biomarkers in Confined Renal Cell Carcinoma (NCT02732652) | Chalmers University of Technology | 2016-06-01 |
| Glycosaminoglycan Scores as Monitoring Biomarkers in Advanced Renal Cell Carcinoma (NCT02732665) | Jens Nielsen | 2016-06-01 |
| A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) (NCT02627963) | AVEO Pharmaceuticals, Inc. | 2016-05-24 |
| Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC (NCT03226236) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2016-03-01 |
| Personalized Targeted Inhibitors Treatment in Renal Cell Cancer (NCT02560012) | The University of Texas Health Science Center, Houston | 2016-01-04 |
| Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors (NCT02700568) | Kidney Cancer Research Bureau | 2016-01-01 |
| A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer (NCT02543645) | Celldex Therapeutics | 2015-10-01 |
| Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) (NCT02454478) | Eisai Co., Ltd. | 2015-07-01 |
| Intraoperative Dual-modality Imaging in Renal Cell Carcinoma (NCT02497599) | Radboud University Medical Center | 2015-06-01 |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma (NCT02386111) | Celldex Therapeutics | 2015-05-01 |
| Prognostic Significance of Preoperative Hemoglobin A1c (HbA1c) in Renal Cell Carcinoma (NCT02417194) | Seoul National University Hospital | 2015-04-01 |
| Follow up After Cryoablation of Small Renal Masses. (NCT02411968) | Radboud University Medical Center | 2015-02-01 |
| Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation of Kidney Lesions (NCT01141816) | St. Joseph's Healthcare Hamilton | 2015-01-01 |
| Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer (NCT01353794) | Bayer | 2014-12-01 |
| Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses (NCT02248389) | Indiana University | 2014-09-04 |
| Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients (NCT02324803) | Southern China Urology Cancer Consortium | 2014-07-01 |
| Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect. (NCT02334709) | University Hospital, Ghent | 2014-02-01 |
| Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma (NCT01982097) | Bayer | 2014-01-10 |
| Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018) (NCT02014636) | Novartis Pharmaceuticals | 2013-12-27 |
| A Study of rSIFN-co in Subjects With Advanced Solid Tumors (NCT02387307) | Sichuan Huiyang Life Science and Technology Corporation | 2013-07-01 |
| RGD-PET-CT in Cancer Angiogenesis (NCT01492192) | Oxford University Hospitals NHS Trust | 2013-05-01 |
| Sorafenib in Elderly mRCC (NCT01728948) | Bayer | 2013-01-06 |
| Imaging Studies of Kidney Cancer Using 18F-VM4-037 (NCT01712685) | National Cancer Institute (NCI) | 2012-10-01 |
| Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma (NCT01649778) | Novartis Pharmaceuticals | 2012-07-19 |
| A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology (NCT01672775) | Agensys, Inc. | 2012-07-18 |
| Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma (NCT01508364) | Bayer | 2012-07-01 |
| Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma (NCT01545817) | Novartis Pharmaceuticals | 2012-04-19 |
| Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell Carcinoma (NCT06111560) | Sun Yat-sen University | 2012-02-01 |
| First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma (NCT01521715) | iOMEDICO AG | 2012-01-24 |
| A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. (NCT01441388) | Pfizer | 2011-12-01 |
| Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting (NCT01557127) | Bayer | 2011-11-01 |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. (NCT01398306) | University Medical Center Groningen | 2011-07-01 |
| A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab (NCT01307267) | Pfizer | 2011-06-21 |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma (NCT01339975) | University Hospital, Bordeaux | 2011-06-06 |
| Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics) (NCT01381601) | GlaxoSmithKline | 2011-03-01 |
| Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS) (NCT01381614) | GlaxoSmithKline | 2011-03-01 |
| Prognostic Factor for Renal Cell Carcinoma (RCC) With Venous Tumor Thrombus (NCT01328691) | Seoul National University Hospital | 2011-03-01 |
| Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors (NCT01334073) | University Hospital, Bordeaux | 2011-03-01 |
| Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy (NCT01195649) | Bayer | 2010-12-13 |
| Cardiovascular and Torsades de Pointes Monitoring for Pazopanib (NCT01446224) | GlaxoSmithKline | 2010-12-01 |
| Hepatic Monitoring for Pazopanib (NCT01449825) | GlaxoSmithKline | 2010-12-01 |
| Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers (NCT01107509) | St. Joseph's Healthcare Hamilton | 2010-10-01 |
| Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma (NCT01147822) | Novartis Pharmaceuticals | 2010-05-19 |
| Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer (NCT01064310) | Novartis Pharmaceuticals | 2010-05-17 |
| Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012 (NCT01056263) | Pfizer | 2010-04-01 |
| Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. (NCT01024920) | Boehringer Ingelheim | 2009-12-16 |
| A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer (NCT01021059) | National Cancer Institute (NCI) | 2009-11-10 |
| A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma (NCT01015911) | Seagen Inc. | 2009-11-01 |
| Regulatory Post Marketing Surveillance Study on Nexavar® (NCT01012011) | Bayer | 2009-09-01 |
| Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer (NCT00835978) | Pfizer | 2009-08-01 |
| Study Evaluating Renal Cell Carcinoma Risk Factors (NCT00927043) | Pfizer | 2009-05-01 |
| A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... (NCT00923481) | National Cancer Institute (NCI) | 2009-04-01 |
| VEG111485: A QTc Study of Pazopanib (NCT00861029) | GlaxoSmithKline | 2009-03-19 |
| A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer (NCT00816686) | Astellas Pharma Inc | 2008-10-01 |
| Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging (NCT00842790) | Assistance Publique - Hôpitaux de Paris | 2008-09-01 |
| Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma (NCT00720941) | Novartis Pharmaceuticals | 2008-08-14 |
| Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (NCT00706706) | Pfizer | 2008-07-01 |
| An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy (NCT00538772) | Kim Chi | 2008-07-01 |
| microRNA Expression in Renal Cell Carcinoma (NCT00743054) | Sun Yat-sen University | 2008-07-01 |
| Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan) (NCT00716625) | Pfizer | 2008-06-01 |
| A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® (NCT00771147) | Bayer | 2008-06-01 |